🔎 Trials Near Me

Beranda › Kanker Payudara › Indiana › Indianapolis

Uji klinis Kanker Payudara di Indianapolis, IN

20 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Indianapolis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Menerima pesertaFase 3
  • Community Health Network, Inc, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06982521

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Menerima pesertaFase 3
  • Investigative Clinical R of Indiana, Indianapolis
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05827081

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Menerima pesertaFase 2Sukarelawan sehat diterima
  • Indiana University Simon Comprehensive Cancer Center, Indianapolis
Usia 18 hingga 45 · Wanita · Diperbarui 1 Okt 2026 · NCT05557877

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Menerima pesertaFase 1
  • Indiana University Simon Comprehensive Cancer Center, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06625775

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Menerima pesertaFase 1/2
  • Community Health Network, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06324357

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Menerima pesertaFase 3
  • Franciscan Health ( Site 0077), Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06966700

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Menerima peserta
  • Indiana University, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07214532

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Menerima pesertaFase 1
  • Indiana University (IU) School of Medicine, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Menerima pesertaFase 3
  • Indiana University Health University Hospital, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Menerima pesertaFase 2
  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Usia 18 ke atas · Wanita · Diperbarui 22 Sep 2026 · NCT07287098

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Menerima pesertaFase 2
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
  • Sidney and Lois Eskenazi Hospital, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT05846789

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Menerima pesertaFase 3
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • Sidney and Lois Eskenazi Hospital, Indianapolis
  • Community Cancer Center East, Indianapolis
  • dan 5 lainnya
Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926

HER2 Vaccine for Locally Advanced Breast Cancer

Menerima pesertaFase 1
  • Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06949410

Exercise in Metastatic Breast Cancer: EMBody

Menerima peserta
  • Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Apr 2026 · NCT05468034

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Menerima pesertaFase 3
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • Franciscan Health Indianapolis, Indianapolis
  • Franciscan Health Mooresville, Mooresville · 16 mi jauhnya
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Menerima pesertaFase 2
  • Indiana University, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT04841148

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Menerima pesertaFase 1/2
  • Research Site, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Mar 2026 · NCT06956690

NearWave Optical Molecular Monitoring

Menerima peserta
  • Indiana University Simon Comprehensive Cancer Center, Indianapolis
Usia 18 ke atas · Wanita · Diperbarui 17 Feb 2026 · NCT06744465

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Menerima pesertaFase 3
  • Franciscan Health Indianapolis, Indianapolis
  • Franciscan Health Mooresville, Mooresville · 16 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT03418961

Uji klinis Kanker Payudara di kota lain

Studi lain di Indianapolis

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.